12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12) is organized by Kenes Group. This onsite medical conference and will be held from Jun 19 - 23, 2022 at Sheraton Centre Toronto Hotel, Toronto, Ontario, Canada.

Description:
ISPPD 2022 international symposium is a prominent event for those interested in practicing pneumococci and pneumococcal diseases It gathers professionals across the field to raise global awareness and promote standards of diagnosis, prevention, and treatment.

ISPPD 2021 pursues the following objectives:
• Aid scientific exchange through a biennial international ISPPD symposium
• Empower other symposia, educational activities, and/or publications as appropriate to the ISPPD mission
• Encourage scientific collaboration and research
• Raise public awareness of the pneumococcal disease, treatment, and prevention

Topics:
• Disease burden
○ Disease burden in infants and children
○ Epidemics, outbreaks, and special settings
○ Global pneumonia control
○ Pneumococcal epidemiology
• Host-pathogen interactions
○ Immunology
○ Pathogenesis
○ Host-pathogen interaction
○ Viral/bacterial interactions and microbiome
• Vaccination strategies and impact
○ Vaccine effect on disease in children
○ Trends in non-vaccine serotypes
○ Mathematical modeling
• Diagnosis and management
○ Diagnosis and diagnostic assays
○ Antimicrobial resistance
○ Conventional and molecular microbiology
○ Treatment of pneumonia and pneumococcal disease
• Genetic sequencing
○ Genetic sequencing
• Pneumococcal colonization
○ Pneumococcal colonization
• Pneumococcal disease and prevention in adults
○ Disease burden in adults
○ Adult vaccination strategies
○ Indirect effects of paediatric programmes on disease in adults
• Pneumococcal disease in high-risk populations
○ Pneumococcal disease in aboriginal populations
○ Pneumococcal disease in persons with high-risk conditions
• Current state of vaccines and vaccine trials
○ Pneumococcal vaccines in development
○ Vaccine use and coverage
○ Economic studies
○ Vaccination policies
• Pneumonia and Pneumococcal Disease in the time of COVID19
○ COVID effects on pneumonia and pneumococcal disease burden
○ Effects of COVID on pneumoccoccal vaccine programmes
○ Management of community acquired pneumonia in the time of COVID
○ Emerging data on SARS-CoV2 and pneumococcus interaction

Additional details will be posted as soon as information is available.